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Key Points
• TRAIL enhances
receptor activator of
NF-kB ligand–induced
osteoclastogenesis
and c-FLIP
upregulation without
osteoclast apoptosis
induction.
• TAK1 inhibition triggers
TRAIL-induced
apoptosis in osteoclasts,
while potentiating
TRAIL-induced
myeloma cell death.
Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) agonists induce tumor-
speciﬁc apoptosis indicating that they may be an attractive therapeutic strategy against
cancers, including multiple myeloma (MM). Osteoclastogenesis is highly induced in MM,
which in turn enhances MM growth, thereby forming a vicious cycle between MM tumor
expansion and bone destruction. However, the effects of TRAIL on MM-enhanced
osteoclastogenesis remain largely unknown. Here, we show that TRAIL induced apoptosis in
MM cells, but not in osteoclasts (OCs), and that it rather facilitated receptor activator of
NF-kB ligand–induced osteoclastogenesis along with upregulation of cellular FLICE
inhibitory protein (c-FLIP). TRAIL did not induce death-inducing signaling complex
formation in OCs, but formed secondary complex (complex II) with the phosphorylation
of transforming growth factor b–activated kinase-1 (TAK1), and thus activated NF-kB
signaling. c-FLIP knockdown abolished complex II formation, thus permitting TRAIL
induction of OC cell death. The TAK1 inhibitor LLZ1640-2 abrogated the TRAIL-induced
c-FLIP upregulation and NF-kB activation, and triggered TRAIL-induced caspase-8 activation
and cell death in OCs. Interestingly, the TRAIL-induced caspase-8 activation caused
enzymatic degradation of the transcription factor Sp1 to noticeably reduce c-FLIP
expression, which further sensitized OCs to TRAIL-induced apoptosis. Furthermore, the
TAK1 inhibition induced antiosteoclastogenic activity by TRAIL even in cocultures with MM
cells while potentiating TRAIL’s anti-MM effects. These results demonstrated that
osteoclastic lineage cells use TRAIL for their differentiation and activation through tilting
caspase-8–dependent apoptosis toward NF-kB activation, and that TAK1 inhibition
subverts TRAIL-mediated NF-kB activation to resume TRAIL-induced apoptosis in OCs while
further enhancing MM cell death in combination with TRAIL.
Introduction
Implementation of novel agents and the availability of autologous stem-cell transplantation have
revolutionized the treatment of multiple myeloma (MM); however, MM still remains incurable for the vast
majority of patients. Because of the incurable nature of MM, clinical application of immunotherapies is
ongoing and expected to open a new avenue for the MM treatment paradigm.
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Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)
binds to its cognate death receptors (DRs) to activate caspase-8
and induce apoptosis in cancer cells.1-6 TRAIL-mediated immuno-
therapy is potentially an attractive therapeutic strategy against
cancers, including MM.7-9 In addition, cytotoxic T cells and natural
killer cells, major effectors in different types of immunotherapies,
highly express TRAIL to induce tumor cell death. However, little
information has been available on the effects of TRAIL on the tumor
microenvironment.
Receptor activator of NF-kB ligand (RANKL), a critical mediator of
osteoclastogenesis, is upregulated to extensively enhance osteo-
clastogenesis and bone resorption in MM.10-12 Thus, activated
osteoclasts (OCs) in turn enhance MM growth, thereby forming a
vicious cycle between MM tumor expansion and osteoclastic bone
destruction.13,14 OCs are not merely bone resorbing cells, but
rather facilitators for tumor growth; therefore, OCs should be
targeted to improve treatment efficacy, especially in MM expanding
in the bone marrow with enhanced bone resorption. However, the
effects of TRAIL on osteoclastogenesis enhanced in MM remain
largely unknown. The present study was therefore undertaken to
clarify the impact of TRAIL on osteoclastogenesis and the MM-OC
interaction.
We demonstrated here that TRAIL did not induce apoptosis, but
rather facilitated RANKL-induced osteoclastogenesis along with
upregulation of cellular FLICE inhibitory protein (c-FLIP), an
endogenous inhibitor for caspase-8, in mouse RAW264.7 cells or
bone marrow macrophages (BMMs). Although TRAIL induced
death in MM cells through death-inducing signaling complex (DISC)
formation and caspase-8 activation, TRAIL did not form the DISC in
OCs, and instead facilitated complex II formation with the
phosphorylation of transforming growth factor b–activated kinase-1
(TAK1) thereby activating NF-kB in OCs. However, TAK1 inhibition
abrogated the TRAIL-induced NF-kB activation and c-FLIP induction
to trigger apoptosis in OCs while potentiating TRAIL-induced
apoptosis in MM cells. These observations provide a rationale
for therapeutic strategies of TRAIL agonists in combination with
TAK1 inhibition for cancers with osteoclastic bone destruction
such as MM.
Materials and methods
Reagents
The following reagents were purchased from the indicated manu-
facturers: rabbit polyclonal anti-TAK1, mouse-specific caspase-8
antibody, rabbit monoclonal anti-c-FLIP, c-fos, RIP1, phosphorylated
IkBa, cleaved caspase-8, mouse-specific cleaved caspase-8 anti-
body, mouse monoclonal anti-human caspase-8 antibody, horserad-
ish peroxidase–anti-rabbit immunoglobulin G (IgG), and anti-mouse
IgG from Cell Signaling Technology (Beverly, MA); rabbit polyclonal
anti-phosphorylated TAK1, DR5 antibody, rabbit monoclonal anti-
Pim-2, and TRAF2 antibody from Abcam (Cambridge, UK); mouse
monoclonal anti-b-actin antibody and terameprocol (TMP) from
Sigma-Aldrich (St. Louis, MO); mouse monoclonal antibodies against
NFATc1, cathepsin K (CTSK), Sp1, and FADD, and the NF-kB
inhibitor BAY 11-7082 from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA); TAK1 inhibitor, LLZ 1640-2 from BioAustralis (Smithfield,
NSW, Australia); recombinant human TRAIL, human macrophage
colony-stimulating factor (M-CSF) from Wako (Osaka, Japan); Z-lle-
Glu(O-ME)-Thr-Asp(O-Me) uoromethyl ketone (Z-IETD-FMK) from
Tonbo Biosciences (San Diego, CA); and human soluble RANKL
(sRANKL) from Oriental Yeast Co. Ltd (Shiga, Japan).
MM cells and cell culture
The human MM cell lines RPMI 8226, U266-B1, and MM.1S and
the murine preosteoclastic cell line RAW264.7 were obtained from
the American Type Culture Collection (Rockville, MD). TSPC-1 was
established in our laboratory.15 The human MM cell lines INA-6
were kindly provided by Renate Burger (University of Kiel, Kiel,
Germany). The mouse MM cell line 5TGM1 was a kind gift from
Gregory R. Mundy (Vanderbilt Center for Bone Biology, Vanderbilt
University, Nashville, TN). Cells were cultured in RPMI 1640
medium (Sigma-Aldrich) supplemented with 10% fetal bovine
serum (FBS; Thermo Fisher Scientific, Waltham MA), penicillin G
at 50 mg/mL and streptomycin at 50 mg/mL.
OC formation
The generation of OCs from RAW264.7 cells16 or mouse bone
marrow cells17 was performed as previously described. The cells were
cultured in Eagle’s minimal essential medium a modification (Sigma-
Aldrich) supplemented with 10% FBS, L-glutamine, and 50 mg/mL
penicillin/streptomycin. RAW264.7 cells were cultured for 4 days in
the presence of sRANKL at 25 to 50 ng/mL to generate mature OCs.
Whole bone marrow cells were harvested from the femur of C57BL/
6J mice (CLEA, Tokyo, Japan), and nonadherent cells were cultured
with M-CSF (10 ng/mL) for 3 days to generate mouse BMMs. The
BMMs were then cultured for 7 days with M-CSF (20 ng/mL) and
sRANKL (50 ng/mL) to generate OCs. Human peripheral blood
mononuclear cells (PBMCs) were isolated from 3 healthy donors as
previously described15 and cultured for 14 days in the presence of
M-CSF (10 ng/mL) and sRANKL (50 ng/mL) to generate OCs. Bone
marrow mononuclear cells were isolated from fresh bone marrow
aspirates of 2 patients withMM as previously described15 and cultured
with M-CSF (10 ng/mL) for 3 days; the cells were then cultured for 14
days in the presence of M-CSF (10 ng/mL) and sRANKL (50 ng/mL)
to generate OCs. To investigate the effects of TRAIL on osteoclato-
genesis and bone resorption, we pretreated RAW264.7 cells with
sRANKL (50 ng/mL) for 2 days, mouse BMMs with M-CSF (20 ng/mL)
and sRANKL (50 ng/mL) for 2 days, and human PBMCs and
patients’ bone marrow cells with M-CSF (10 ng/mL) and sRANKL
(50 ng/mL) for 4 days. After the pretreatment, culture media were
changed. The cells were then cultured in the presence or absence
of TRAIL. Tartrate-resistant acid phosphatase (TRAP)–positive cells
were detected with a Leukocyte Acid Phosphatase Assay kit (Sigma-
Aldrich). TRAP-positive cells containing 3 or more nuclei were
counted under a light microscope (BX50; Olympus, Tokyo, Japan).
The cells were cultured in quadruplicate for each treatment on OC
differentiation. All procedures involving human specimens were
performed with written informed consent according to the
Declaration of Helsinki and using a protocol approved by the
Institutional Review Board for human protection.
Bone resorption assay
Bone resorption assay was performed using Corning Osteo-
Assay Surface 96-well plates (Cat. No. 3989; Corning, Lowell,
MA), as we described previously.16 The areas of dentin resorption
were determined using image analysis techniques (National
Institutes of Health ImageJ system; http://imagej.nih.gov/ij/), after
attached cells were removed from the slides using 6% sodium
hypochlorite.
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Figure 1. Mature OCs express proapoptotic DRs. (A) CTSK and DR5 were immunostained in green and red, respectively, in a bone section. For staining OCs in bone, the
tibiae of ICR-nu/nu mice (CLEA) were taken out, fixed for 2 days in 10% paraformaldehyde/PBS, and decalcified in 10% EDTA (pH 7.4) for 1 week. The tibiae specimens
were embedded in paraffin, and then 5 mm thick serial sections were prepared. The deparaffinized sections were blocked with PBS containing 4.0% bovine serum albumin
(PBS-BSA) for 1 hour at room temperature. To detect the localization of DR5 and CTSK in the tibia, the sections were incubated with anti-DR5 and anti-CTSK antibodies
diluted 1:100 in PBS-BSA overnight at 4°C. After being washed 3 times with PBS, sections were reacted with Alexa Fluor 594–conjugated anti-rabbit IgG and Alexa Fluor
488–conjugated anti-mouse IgG secondary antibodies. The sections were observed under a fluorescence microscope (BX50, Olympus). Original magnification 3100. BM,
bone marrow. (B) Murine RAW264.7 preosteoclastic cells were treated with sRANKL (50 ng/mL) for 72 hours, and DR5 mRNA expression was analyzed by RT-PCR (upper).
Human monocytes from a healthy donor were treated with M-CSF (10 ng/mL) and sRANKL (50 ng/mL) for 5 days, and DR4 and DR5 mRNA expression was analyzed by
RT-PCR (lower). GAPDH was used as an internal control. DR4 and DR5 mRNA expression was also determined using real-time PCR. GAPDH was used as an endogenous
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Immunofluorescence staining
For immunofluorescence staining, RAW264.7 cells were cultured
with sRANKL (50 ng/mL) for 3 days on glass bottom dishes. The cells
were fixed for 10 minutes with 4% formaldehyde in phosphate-
buffered saline (PBS) and permeabilized with 0.1% Triton X-100 in
PBS. After blocking with 5% goat serum for 30 minutes, the cells
were incubated with anti-DR5 antibody (1:100), anti-p65 and anti-
CTSK antibody (1:100) overnight at 4°C. The cells were washed in
PBS and incubated with Alexa Fluor 594-conjugated anti-rabbit IgG
and Alexa Fluor 488–conjugated anti-mouse IgG secondary anti-
bodies (1:100 in PBS; Thermo Fisher Scientific) for 1 hour. The
F-actin ring was visualized with Alexa Fluor 488-conjugated phalloidin
(Thermo Fisher Scientific). The nuclei were stained with Hoechst
33342 (Dojindo, Kumamoto, Japan) or 4’,6-diamino-2-phenylindole
(Thermo Fisher Scientific). The wide field-of-view fluorescence images
were examined using a fluorescence microscope (BX50, Olympus)
Reverse transcription polymerase chain
reaction (RT-PCR)
Total RNA was extracted using TRIZOL reagent (Gibco BRL,
Rockville, MD). Two micrograms of total RNA was reverse-
transcribed with Superscript II (Gibco) in a 20 mL reaction
solution. The RT-PCR products were used for subsequent PCR
analysis with 23 to 30 cycles of 95°C for 30 seconds, 58°C for
30 seconds, and 72°C for 30 seconds. The following primer
sequenceswere used:mouseDR5 F: AGTAGTGCTGCTGATTGGAG
and R: CCTGTTTTCTGAGTCTTGCC, human DR4 F: TGGCACA-
CAGCAATGGGAACATAG and R: GAAACACACCCTGTCCATG-
CACTT, DR5 F: TGAGTCTGCTCTGATCACCCAACA and R:
ACTTCCGGCACATCTCAGGAGAAT, mouse c-FLIP F: AGTC-
CAGCCAAGGAGCAAGA and R: TGTAAGTCTCTTCACGGATG,
human c-FLIP F: AATTCAAGGCTCACAAGCGA and R: GGCA-
GAAACTCTGCTGTTCC, andGAPDH F: TGTCTTCACCACCATG-
GAGAAGG and R: GTGGATGCAGGGATGATGTTCTG.
Real-time PCR
Each complementary DNA sample was amplified using SYBR Premix
EX Taq II (Takara Bio Inc., Shiga, Japan) on the 7300 Real-time PCR
System (Thermo Fisher Scientific). Briefly, the reaction conditions
consisted of 2 mL of complementary DNA and 0.4 mM primers in a
total volume of 20 mL. GAPDH was used as an endogenous control
to normalize each sample.
Cell viability
Cell viability was determined by Cell Counting Kit-8 assay (Dojindo)
according to the manufacturer’s instructions. Briefly, cells were
plated on a 96-well plate and incubated with 2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium
monosodium salt (WST-8). After the incubation, the absorbance of
each well was measured at 450 to 655 nm with an iMark microplate
reader (Bio-Rad Laboratories, Hercules, CA).
TUNEL staining
To identify apoptotic cells, in situ cell death detection kit (Roche
Diagnostics GmbH, Mannheim, Germany) was used. The cells were
fixed with 4% paraformaldehyde for 1 hour and permeabilized with
0.1% Triton X-100 in PBS. The terminal deoxynucleotidyltransferase-
mediated dUTP nick end labeling (TUNEL)–positive multinucleated
cells (MNCs) were counted.
Western blot analysis
Cells were collected and lysed in radioimmunoprecipitation assay
(RIPA) buffer supplemented with a protease inhibitor cocktail (Santa
Cruz). The cell lysates were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis on a 10% polyacrylamide gel
and transferred to polyvinylidene difluoride membranes (Millpore,
Billerica, MA). Membranes were blocked with 5% nonfat dry milk
in tris(hydroxymethyl)aminomethane–buffered saline with 0.01%
Tween 20 for 1 hour at room temperature and incubated for 16
hours at 4°C with primary antibodies. After washing, secondary
horseradish peroxidase–conjugated antibody was added, and
membranes were then developed, using the enhanced chem-
iluminescence plus western blotting detection system (GE
Healthcare Life Sciences, Chicago, IL).
Immunoprecipitation
Briefly, cells were lysed in RIPA buffer supplemented with a
protease inhibitor cocktail (Santa Cruz). For DR5, FADD immuno-
precipitation, 1 mg of protein was incubated with 4 mg of anti-DR5
or FADD antibodies overnight at 4°C followed by the addition of
20 mL of protein A/G agarose beads (Santa Cruz) and then
incubated for 1 hour at 4°C. The immune complexes were washed
with RIPA buffer and subjected to western blotting.
Small interfering RNA (siRNA) transfection
RAW264.7 cells were seeded at a density of 23 105 cells per well on
6-well plates in Eagle’s minimal essential medium a modification at
37°Cwith 5%CO2 overnight. c-FLIP siRNAwas purchased fromSanta
Cruz and transfected into RAW264.7 cells using siRNA Transfection
Reagent (Santa Cruz), following the manufacturer’s protocol.
Statistical analysis
Statistical analysis was performed using the Student t test or 1-way
analysis of variance. P # .05 was considered as a significant
difference. All statistics were performed using the Statistical Package
for Social Sciences (SPSS 13.0 for Windows; Chicago, IL).
Results
Mature OCs express proapoptotic DRs
TRAIL binds to its cognate DRs to activate caspase-8 and induce
apoptosis in cancer cells, which is intracellularly inhibited by
c-FLIP.18 DR4 and DR5 are generally accepted as proapoptotic
Figure 1. (continued) control to normalize each sample. Data were expressed as mean 6 standard error. *P , .05. (C) Mature OCs derived from RAW264.7 cells were fixed
and stained with anti-DR5 antibody (red, upper panels). F-actin and nuclei were stained with phalloidin (green) and Hoechst 33342 (Hoechst, red), respectively (lower panels).
Samples were visualized with a fluorescence microscope (BX50, Olympus). Original magnification 3100. Bar represents 100 mm. (D) RAW264.7 cells (left) or mouse BMMs
(right) were treated with sRANKL (50 ng/mL) for the indicated time periods, and then cell lysates were collected. The expression of DR5, c-FLIP, NFATc1, and CTSK was
analyzed by western blotting. b-actin served as a loading control.
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Figure 2. TRAIL induces cell death in MM cells but not in OCs. (A) Human MM cell lines, MM.1S, INA-6, and TSPC-1, and murine 5TGM1 MM cell line were treated
in triplicate with the indicated concentrations of TRAIL for 48 hours. Cell viability was determined by WST-8 assay. Data were expressed as mean 6 standard deviation
(SD). *P , .05. (B) To generate mature OCs, RAW264.7 cells were cultured for 4 days with sRANKL at 50 ng/mL, BMMs for 7 days with a combination of M-CSF
(20 ng/mL) and sRANKL (50 ng/mL), and human PBMCs for 14 days in the presence of M-CSF (10 ng/mL) and sRANKL (50 ng/mL). Mature OCs from RAW264.7,
mouse BMMs, and human PBMCs were treated in triplicate with the indicated concentrations of TRAIL for 48 hours. Representative results are shown. The numbers of
TRAP-positive MNCs were counted (upper, left). Cell viability was also determined by TUNEL assay (upper, right). Data were expressed as mean 6 SD. The experiment
was performed by 3 independent experiments with triplicate. Mature OCs from RAW264.7 cells were treated with TRAIL (500 ng/mL) for 48 hours, and F-actin and nuclei
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receptors for TRAIL in humans, whereas DR5 is regarded in mice as
a single ortholog of human DR4 and DR5.19 To clarify the effects of
TRAIL on OCs, we first examined the expression of DR5 in OCs in
mouse bones. DR5 is expressed in CTSK-expressing OCs
(Figure 1A).
RAW264.7 cells, an authentic murine preosteoclastic cell line, and
human monocytes obtained from peripheral blood of a normal
subject only weakly expressed DR5, and both DR4 and DR5 at
messenger RNA (mRNA) levels, respectively (Figure 1B). However,
treatment with RANKL upregulated DR5 expression in OCs derived
from RAW264.7 cells. DR4 and DR5 expression was increased in
OCs induced from human monocytes upon treatment with M-CSF
and RANKL. Furthermore, DR5 was clearly expressed at the
periphery of mature OCs with F-actin ring formation derived from
RAW264.7 cells (Figure 1C). The upregulation of DR5 is consistent
with the previous observation by Colucci et al.20 DR5 protein levels
were increased over time in RAW264.7 cells and mouse BMMs
upon treatment with RANKL in parallel with induction of NFATc1
and CTSK, markers of osteoclastic differentiation (Figure 1D).
Interestingly, c-FLIP, an endogenous caspase-8 inhibitor, was also
upregulated during osteoclastogenesis in parallel with the expres-
sion of DR5. These results demonstrated that the expression of DRs
and the endogenous caspase-8 inhibitor c-FLIP is upregulated in
OCs.
TRAIL induces cell death in MM cells but not in OCs
As previously reported,8,21 TRAIL dose dependently induced cell
death in MM cell lines, MM.1S, INA-6, and TSPC-1, and murine MM
cell line 5TGM1 at 10 ng/mL and more (Figure 2A). In sharp
contrast, although mature OCs express DRs (Figure 1A), TRAIL did
not induce cell death in OCs derived from RAW264.7 cells, murine
BMMs, or human PBMCs even at 100 ng/mL (Figure 2B, upper),
nor did it affect F-actin ring formation in OCs even at 500 ng/mL
(Figure 2B, lower), indicating the resistance of OCs to TRAIL-
induced apoptosis.
It is intriguing that TRAIL induces cell death in MM cells but not in
mature OCs, although both types of cells express proapoptotic
DRs. c-FLIP is generally accepted as one of the most important
factors to prevent caspase-8 activation and thereby inhibit
apoptosis.22 DR-bound FADD forms a DISC with caspase-8.23
c-FLIP competes with caspase-8 for binding to FADD and interferes
with caspase recruitment to the DISC, thereby antagonizing DISC
formation to inhibit caspase-8 activation after DR-mediated
stimulation.24 c-FLIP, an endogenous caspase-8 inhibitor, was
induced during osteoclastogenesis in parallel with the expression of
DR5 (Figure 1D), suggesting that upregulated c-FLIP in mature
OCs plays a key role in their resistance to TRAIL-induced apoptosis.
Therefore, we next looked at the formation of a DISC in mature OCs
derived from RAW264.7 cells and MM cells. Immunoprecipitation
analyses with an anti-DR5 antibody demonstrated that TRAIL did
not induce the formation of a DISC, consisting of DR5, FADD, and
caspase-8, in OCs, but the DISC was formed in MM.1S cells at
10 minutes after addition of TRAIL (Figure 2C). Interestingly, c-FLIP
protein levels were substantially increased in the OCs, but reduced
in MM cells after the TRAIL treatment (Figure 2D). These results
suggest a reverse correlation between TRAIL-induced cell death
and c-FLIP levels.
c-FLIP knockdown impairs osteoclastogenesis and
resumes TRAIL-induced apoptosis in mature OCs
As DR5 expression was upregulated during osteoclastogenesis
(Figure 1D) and because TRAIL does not induce cell death in OCs
(Figure 2B), we examined whether TRAIL affects osteoclasto-
genesis by itself. RAW264.7 cells or mouse BMMs were treated
with RANKL for 2 days to upregulate their DR5 expression, and
thereafter deprived of RANKL and cultured with TRAIL. TRAIL was
able to dose dependently increase the formation of TRAP-positive
MNCs, namely mature OCs, in the absence of RANKL (Figure 3A).
Similar results were obtained in osteoclastogenesis from PBMCs
from normal human donors (Figure 3A) and bone marrow mono-
nuclear cells from patients with MM (supplemental Figure 1A). Bone
resorption activity was also increased in a similar fashion to the OC
formation by TRAIL (Figure 3A). Emergence of NFATc1 and CTSK
expression in the mouse BMMs also indicated the induction of
osteoclastogenesis upon treatment with TRAIL (Figure 3A). These
results demonstrated that osteoclastic lineage cells use TRAIL to
facilitate their osteoclastogenesis. In addition, TRAIL was able to
stimulate mature OCs to slightly enhance bone resorptive activity
(supplemental Figure 1B, left). When we compared the distribution
of nuclei per cell for OCs generated by TRAIL and sRANKL at
100 ng/mL, sRANKL and TRAIL similarly enhanced the formation of
TRAP-positive MNCs with 3 to 5 nuclei as well as those with .5
(supplemental Figure 1B, right).
As c-FLIP expression is induced during osteoclastogenesis in parallel
with the expression of DR5 (Figure 1D), c-FLIP is suggested to be
involved in osteoclastogenesis and resistance to TRAIL-induced cell
death in OCs. To clarify the role of c-FLIP in osteoclastogenesis and
OC survival, we examined the effects of c-FLIP knockdown on
RANKL-induced osteoclastogenesis and the susceptibility of OCs to
TRAIL. c-FLIP siRNA was transfected into RAW264.7 cells, and then
the cells were cultured with RANKL to give rise to OCs. The c-FLIP
knockdown substantially reduced c-FLIP protein levels and abolished
TRAIL-induced c-FLIP upregulation in the OCs (Figure 3B, left). The
c-FLIP knockdown alone reduced osteoclastogenesis by RANKL
(Figure 3B, middle). Addition of TRAIL was able to dose dependently
induce cell death in the OCs differentiated from RAW264.7 cells with
c-FLIP knockdown (Figure 3B, middle and right). These results
suggest the critical role of c-FLIP in OC differentiation and maturation
by RANKL, as well as the resistance of OCs to TRAIL-induced
apoptosis.
FADD has been demonstrated to interact with TRAF2 and RIP1 to
form a secondary complex (complex II), but not DISC, as well as to
Figure 2. (continued) were stained with phalloidin (green) and 4’,6-diamino-2-phenylindole (blue), respectively (lower, left). Samples were visualized with a fluorescence
microscope (BX50, Olympus). Original magnification 3100. Bar represents 100 mm. MNCs with an intact actin ring were counted (lower, right). (C) Mature OCs from
RAW264.7 cells and MM.1S were starved with 1% FBS for 24 hours, and then incubated with TRAIL at 100 ng/mL for the indicated periods. For immunoprecipitation,
cell lysates were collected and an equal amount of each protein lysate was incubated with anti-DR5 antibody. DISC formation was analyzed by western blotting with anti-
FADD, anti-caspase-8, and anti-DR5 antibodies. (D) Mature OCs from RAW264.7 cells and the indicated MM cell lines were treated with TRAIL at 100 ng/mL for
48 hours. The protein levels of c-FLIP were analyzed by western blotting. b-actin was used as a protein loading control.
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Figure 3. c-FLIP knockdown impairs osteoclastogenesis and resumes TRAIL-induced apoptosis in mature OCs. (A) RAW264.7 cells were pretreated with sRANKL
(50 ng/mL) for 48 hours, mouse BMMs were pretreated with M-CSF (20 ng/mL) and sRANKL (50 ng/mL) for 48 hours, and human PBMCs were pretreated in quadruplicate
with M-CSF (10 ng/mL) and sRANKL (50 ng/mL) for 4 days. After the pretreatment, the media were changed, and TRAIL was added at the indicated concentrations.
RAW264.7 cells, mouse BMMs, and human PBMCs were further cultured for 4, 7, and 14 days, respectively. The numbers of TRAP-positive MNCs were counted. Data were
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initiate canonical NF-kB activation in a portion of transformed cells
in a context-dependent manner.25 Therefore, we investigated the
effects of TRAIL on complex II formation in OCs. Immunoprecip-
itation analyses with an anti-FADD antibody revealed that upon
TRAIL treatment, FADD formed a complex with TRAF2 and RIP1,
namely complex II, in OCs at 5 minutes but not in MM cells
(Figure 3C). However, TRAIL did not induce complex II formation in
OCs differentiated from RAW264.7 cells with c-FLIP knockdown,
indicating the critical role of c-FLIP in induction of complex II
formation by TRAIL in OCs (Figure 3D). These results collectively
suggest that the upregulation of c-FLIP facilitates osteoclasto-
genesis and confers resistance to TRAIL-induced cell death in OCs.
TRAIL activates the TAK1/NF-kB signaling in OCs
TAK1 plays a critical role in activation of the canonical NF-kB and
MAPK pathways downstream of complex II.26 Therefore, we next
looked at the effects of TRAIL on the activation of TAK1 and thereby
NF-kB signaling in RAW264.7 cell-derived OCs with DR5 expres-
sion. Consistent with the formation of complex II (Figure 3C),
treatment with TRAIL induced the phosphorylation of TAK1 in OCs
but not in MM cells (Figure 4A). The induction of TAK1
phosphorylation by TRAIL was followed by the phosphorylation of
IkBa in OCs (Figure 4B, left). Nuclear localization of p65, a subunit of
NF-kB, was also confirmed in OCs upon the TRAIL treatment
(Figure 4B, right). However, the TAK1 inhibitor LLZ1640-2 abolished
the TRAIL-induced phosphorylation of IkBa (Figure 4B, left) and the
nuclear localization of p65 (Figure 4B, right) in OCs.
We and others recently reported that Pim-2 is upregulated not only
in MM cells but also in OCs in MM bone lesions.16,27-29 RANKL
activates the NF-kB signaling and thereby transcriptionally induces
Pim-2 in osteoclastic lineage cells during their osteoclastogenesis;
and Pim-2 inhibition abolishes RANKL-mediated osteoclastogene-
sis, indicating Pim-2 as a critical mediator of osteoclastogenesis.16
Consistent with Pim-2 upregulation by NF-kB activation, treatment
with TRAIL upregulated Pim-2 expression in OCs (Figure 4C).
However, LLZ1640-2 abrogated the Pim-2 upregulation by TRAIL,
suggesting involvement of the TRAIL/TAK1/NF-kB/Pim-2 pathway
in osteoclastogenesis.
TRAIL enhanced c-FLIP expression (Figure 2D) and activated the
NF-kB signaling in OCs (Figure 4B). c-FLIP has been demonstrated
to be upregulated in different types of cells through NF-kB
activation.18 Sp1 is known to be a transcription factor downstream
of NF-kB signaling30 and to be responsible for c-FLIP gene
expression.18 Consistent with these observations, the NF-kB
inhibitor BAY11-7085 as well as LLZ1640-2 suppressed c-FLIP
induction in OCs by TRAIL (Figure 4D, upper). Furthermore, c-FLIP
expression almost completely disappeared by treatment with TMP,
an inhibitor of Sp1 binding to DNA (Figure 4D, lower), suggesting a
critical role of Sp1 in c-FLIP expression in OCs. These results
demonstrated that TRAIL induces the TAK1/NF-kB/Sp1/c-FLIP
induction axis besides upregulating the osteoclastogenic mediator
Pim-2 in OCs and suggest that TRAIL activates TAK1/NF-kB
signaling in OCs while mitigating DR-induced caspase-8 activation
through c-FLIP induction.
TAK1 inhibition triggers TRAIL-induced death in OCs
and potentiates it in MM cells
As TRAIL appears to activate the complex II/TAK1-mediated
signaling pathway in OCs, we next looked at the role of TRAIL-
induced TAK1 activation in the survival of OCs. As shown in
Figure 2B, TRAIL alone did not affect the viability of OCs; however,
TRAIL triggered and dose dependently reduced OC numbers and
increased TUNEL-positive OCs in the presence of the TAK1 inhibitor
LLZ1640-2 (Figure 5Ai-ii). Treatment with TRAIL upregulated c-FLIP
protein levels without activation of caspase-8 in OCs (Figure 5Aiii).
However, the TAK1 inhibition substantially reduced c-FLIP expression
and triggered activation of caspase-8 in OCs. TRAIL substantially
reduced Sp1 and c-FLIP protein levels in parallel with caspase-8
activation in the presence of the TAK1 inhibitor LLZ1640-2, which
were restored by the caspase-8 inhibitor Z-IETD-FMK (Figure 5B),
indicating enzymatic degradation of Sp1 and thereby c-FLIP re-
duction. This is consistent with our recent observation in MM cells of
caspase-8-driven degradation of Sp1 protein and thereby reduction of
Sp1-target gene expression.31
In contrast, TRAIL dose dependently induced death in MM cells,
which was further augmented in the presence of LLZ1640-2
(Figure 5C). TRAIL was able to activate caspase-8, and sub-
stantially reduced Sp1 and c-FLIP protein levels in MM cells, which
was further enhanced by the TAK1 inhibition (Figure 5D, left). TRAIL
potently reduced c-FLIP mRNA expression in MM cells; however, the
reduction of c-FLIPmRNA by TRAIL was abolished under the caspase-
8 inhibition (Figure 5D, right; supplemental Figure 1C), indicating
caspase-8–dependent reduction of c-FLIP in MM cells by TRAIL. From
these results, TAK1 inhibition permits TRAIL-induced apoptosis in OCs
while further enhancing TRAIL-induced MM cell death.
TRAIL disrupts MM cell–OC interaction under
TAK1 inhibition
MM cells enhance osteoclastogenesis and OC activation through
upregulation of RANKL expression in MM bone lesions. Cocultures
Figure 3. (continued) expressed as mean 6 SD. *P , .05. The representative photos of TRAP staining are shown. Bars represent 100 mm. Original magnification 3100.
Bone resorption activity was also analyzed using Osteo assay plates. Resorption area was visualized by von Kossa staining, and observed using a light microscope (BX50,
Olympus). The results were expressed as % area of bone resorption. The cell lysates were collected, and NFATc1 and CTSK were analyzed by western blotting. b-actin served
as a loading control. (B) c-FLIP siRNA or control siRNA was transfected into RAW264.7 cells. After the transfection, the cells were treated with sRANKL (50 ng/mL) for
4 days. The cells were then washed and treated with the indicated concentrations of TRAIL for 48 hours. The protein levels of c-FLIP were analyzed by western blotting (left).
b-actin was used as a protein loading control. The numbers of TRAP-positive MNCs were counted. To identify apoptotic cells, the cells were stained with TUNEL staining. The
TUNEL-positive multinuclear cells were counted. Data were expressed as mean 6 SD. *P , .05. (C) Mature OCs from RAW264.7 cells and MM.1S cells were starved with
1% FBS for 24 hours and then incubated with TRAIL at 100 ng/mL for the indicated time periods. The cell lysates were collected and an equal amount of each protein lysate
was incubated with anti-FADD antibody. Complex II formation was analyzed by western blotting with anti-RIP1, anti-TRAF2, and anti-FADD antibodies. (D) RAW264.7 cells
transfected either c-FLIP or control siRNA were treated with sRANKL (50 ng/mL) for 48 hours. The cells were then washed and treated with at 100 ng/mL for the indicated
time periods. The complex II formation was analyzed.
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with MM cells enhanced the formation of TRAP-positive MNCs,
namely mature OCs, from bone marrow cells (Figure 6A). Treatment
with TRAIL further enhanced osteoclastogenesis in the cocultures;
however, TAK1 inhibition abolished the enhancement of osteoclas-
togenesis by TRAIL in the presence of MM cells.
We and others demonstrated that MM cells and OCs interact with
each other to augment their growth and activity, thereby forming a
vicious cycle that leads to extensive bone destruction and MM
expansion.13,14,32 Therefore, we next examined the impact of TRAIL
in combination with TAK1 inhibition on the viability of MM cells in
cocultures with OCs. Cocultures with OCs lowered TRAIL-induced
MM cell death (Figure 6B). However, addition of the TAK1 inhibitor
LLZ1640-2 substantially reducedMMcell viability in combination with
TRAIL in cocultures with OCs, although there was still protection by
OCs from the MM cell killing observed when both TRAIL and
LLZ1640-2 are present. These results suggest that TAK1 inhibition
may disrupt MM cell-OC interaction and potentiate TRAIL’s antitumor
effects while also converting TRAIL to an anti–bone resorptive agent.
Discussion
MM has a unique propensity to develop and expand almost
exclusively in the bone marrow and generates destructive bone
disease. MM cells enhance osteoclastogenesis33,34 while suppress-
ing osteoblastogenesis,35-39 leading to devastating bone destruction
with rapid loss of bone. Along with the progression of bone disease,
the bone marrow microenvironment is skewed by MM cells, which
underlies the unique pathophysiology of MM and confers aggres-
siveness and drug resistance in MM cells.40,41 Although MM cells
perturb bone metabolism to develop bone destruction, cross talk
between MM cells and the microenvironment in bone lesions leads to
a progressive vicious cycle phase of tumor growth and bone
destruction.13,14,32 The present study demonstrated that osteoclastic
lineage cells use TRAIL for their differentiation into OCs through
tilting TRAIL-mediated caspase-8–dependent apoptosis into activa-
tion of the NF-kB signaling. Therefore, use of TRAIL agonists to treat
patients with MM and other cancers with osteolytic bone metastases
may result in enhanced progression of osteolytic bone destruction.
There have been conflicting data in the literature as to whether TRAIL
increases the formation of human andmurine OCs from their precursors
and induction of apoptosis in them. Some reported that TRAIL induces
apoptosis in OCs and suppresses osteoclastogenesis.20,42,43 Others
demonstrated that TRAIL induces osteoclastogenesis.44-46Weobtained
the results showing facilitation of RANKL-primed osteoclastogenesis
without induction of OC death by TRAIL. According to our present
results, RANKL activates TAK1 and induces c-FLIP expression in
OCs and their precursors, which is able to protect them from TRAIL-
induced apoptosis. In such a condition, TRAIL further upregulates
c-FLIP expression. Further, TRAIL was also found to facilitate
osteoclastogenesis even in the presence of RANKL (supplemental
Figure 1D). However, because antagonism between TRAIL and
RANKL has been demonstrated,47 we need to dissect the molecular
mechanisms of the combinatory effects of TRAIL and RANKL.
Checking the activation status of TAK1 and thereby upregulation of
c-FLIP in each individual experimental condition may help to explain
the conflicting results of TRAIL effects on osteoclastogenesis and the
viability of OCs.
As RANKL induces the expression of DRs and c-FLIP
in osteoclastic lineage cells along with osteoclastogenesis
(Figure 1D), an anti-RANKL antibody may ameliorate TRAIL’s
osteoclastogenic actions. Therefore, combinatory treatment with an
anti-RANKL antibody warrants further study. However, in the
present study, we demonstrated that TAK1 inhibition subverts
TRAIL-mediated NF-kB activation to regain TRAIL-induced apo-
ptosis in OCs while further enhancing MM cell death in combination
with TRAIL. Combination of TAK1 inhibitors with TRAIL agonists
may become an effective therapeutic option yielding an improved
clinical outcome for MM.
DRs can mediate diverse signals in a cell type–specific and
context-dependent manner.48 Here, we dissected the mecha-
nisms of resistance to TRAIL-induced apoptosis in OCs. TRAIL
was demonstrated to induce the formation of FADD-driven
complex II in OCs to activate TAK1 and its downstream signaling
pathways, including the NF-kB pathway. During osteoclasto-
genesis, the expression of c-FLIP, an endogenous inhibitor of
DISC formation, was substantially increased in parallel with DR
expression. The c-FLIP upregulation appears to block DISC
formation to allow FADD-driven complex II formation. Therefore,
c-FLIP upregulation is suggested to primarily play an important
role in rendering OCs activated and refractory to TRAIL-induced
apoptosis.
The activation of the TRAIL/TAK1/NF-kB pathway by TRAIL not
only stimulates osteoclastogenesis and OC survival but also
enhances c-FLIP expression in OCs, which further suppresses
TRAIL-induced apoptosis. Intriguingly, MM cells tend to undergo
apoptosis along with reducing c-FLIP in response to TRAIL in sharp
contrast to OCs.
We recently reported that caspase-8 activation enzymatically
degrades the transcription factor Sp1 and thereby reduces its
target gene expression in MM cells.31 We demonstrated here that
this c-FLIP reduction in MM cells is largely because of caspase-
8–mediated enzymatic degradation of Sp1, a transcription factor
responsible for c-FLIP gene expression, because treatment with a
caspase-8 inhibitor almost completely restored the c-FLIP levels
reduced in MM cells by TRAIL (Figure 5D). Therefore, TRAIL-
induced activation of caspase-8 is suggested to lead to further
potentiation of the DR/caspase-8–mediated apoptotic pathway in MM
Figure 4. (continued) phosphorylated IkBa (p-IkBa) was detected by western blotting (left). b-actin was used as a protein loading control. To observe p65 localization, the
cells were fixed and stained with anti-p65 antibody (green), and their nuclei were stained with Hoechst 33342 (red). These images are taken by wide field-of-view fluorescence
microscope (BX50, Olympus). Bar represents 100 mm. (C) Mature OCs from RAW264.7 cells were cultured in the presence or absence of LLZ at 300 nM for 48 hours.
TRAIL was added as indicated. The protein levels of Pim-2 were analyzed by western blotting. b-actin was used as a protein loading control. (D) Mature OCs from RAW264.7
cells were cultured in the presence or absence of TRAIL (100 ng/mL) for 6 and 24 hours to perform RT-PCR and western blotting, respectively. LLZ at 300 nM and
BAY11-7085 at 20 nM (upper), and the Sp1 inhibitor TMP at 100 mM (lower) were added as indicated. c-FLIP expression was analyzed. c-FLIP mRNA expression was also
analyzed by real-time PCR. The results are expressed using D-D Ct method. GAPDH and b-actin served as loading controls, respectively.
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cells. Of note, TRAIL was able to reduce c-FLIP levels and activate
caspase-8 in OCs under TAK1 inhibition (Figure 5A). Although c-FLIP
production is transcriptionally upregulated to inhibit DISC formation
and thereby apoptosis in OCs by TRAIL, TAK1 inhibition is able to
suppress c-FLIP production through disrupting complex II–mediated
NF-kB signaling and triggering the caspase-8–mediated degradation
of Sp1, which causes induction of apoptosis in OCs.
Although c-FLIP expressionwas increased alongwith RANKL-mediated
OC differentiation, c-FLIP knockdown significantly impaired RANKL-
mediated osteoclastogenesis. Therefore, c-FLIP is suggested to play
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Figure 6. TRAIL disrupts MM cell-OC interaction under TAK1 inhibition. (A) Murine bone marrow mononuclear cells were plated onto 24-well culture plates
(1 3 106 cells per well). The cells were treated with M-CSF for 3 days, followed by sRANKL (25 ng/mL) for 2 days to generate adherent preosteoclastic cells. After washing,
the adherent preosteoclastic cells were cocultured for 3 days with murine 5TGM1 MM cells at 1 3 104 cells per well. TRAIL at 100 ng/mL and LLZ at 300 nM were added
as indicated. TRAP-positive MNCs (5 or more nuclei) were counted as OCs. Data were expressed as mean 6 standard error. *P , .05. Microscopic images of TRAP staining
in representative cultures are shown (lower panels). Original magnification 3100. Bar represents 100 mm. (B) Human OCs were generated in 24-well culture plates with
M-CSF and sRANKL from PBMCs from a healthy donor. The OCs were tightly attached on the culture plates. MM cell lines, INA-6, RPMI 8226, and MM.1S, were cultured
alone or cocultured with the OCs for 48 hours. TRAIL at 100 ng/mL and LLZ at 300 nM were added as indicated. MM cells were collected, and their viability was measured by
WST-8 assay. Data were expressed as mean 6 SD. *P , .05.
Figure 5. (continued) (B) Mature OCs from RAW264.7 cells were cultured in the presence or absence of LLZ at 150 nM for 48 hours. TRAIL at 100 ng/mL and the
caspase-8 inhibitor Z-IETD-FMK at 100 mM were added as indicated. The protein levels of caspase-8, cleaved caspase-8, Sp1, and c-FLIP were analyzed by western blotting.
b-actin was used as a protein loading control. (C) MM cell lines, RPMI 8226, MM.1S, and 5TGM1, were cultured in the presence or absence of LLZ at 300 nM for 48 hours.
TRAIL was added at the indicated concentrations. The cell viability was measured by WST-8 cell proliferation assay. Results were expressed as the mean 6 SD. *P , .05.
(D) The indicated MM cell lines were cultured in the presence or absence of LLZ at 300 nM for 6 and 24 hours to perform RT-PCR and western blotting, respectively. TRAIL
was added at 100 ng/mL as indicated. The protein levels of caspase-8, cleaved caspase-8, Sp1, and c-FLIP were analyzed by western blotting (left). b-actin was used as a
protein loading control. Z-IETD-FMK was added at 100 mM as indicated. c-FLIP mRNA expression was analyzed by RT-PCR. GAPDH served as an internal control.
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a critical role in osteoclastogenesis other than inhibition of the DISC
formation in osteoclastic lineage cells. c-FLIP has been reported to
interact with intracellular signaling components, such as TRAF2 and
RIP1, to perform cellular functions in different types of cells,25 which
warrants for further study on the functional role of c-FLIP in
osteoclastogenesis.
In conclusion, TAK1 inhibition subverts TRAIL-mediatedNF-kBactivation
to restore TRAIL-induced apoptosis in OCs while further enhancing MM
cell death in combination with TRAIL, providing a rationale for therapeutic
strategies of TRAIL agonists in combination with TAK1 inhibition for
cancers with osteoclastic bone destruction such as MM.
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